Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EPS (Basic): 2023-2025

Historic EPS (Basic) for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$0.65.

  • Immunome's EPS (Basic) rose 16.67% to -$0.65 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.95, marking a year-over-year increase of 63.63%. This contributed to the annual value of -$5 for FY2024, which is 7.06% up from last year.
  • Latest data reveals that Immunome reported EPS (Basic) of -$0.65 as of Q3 2025, which was down 30.00% from -$0.50 recorded in Q2 2025.
  • In the past 5 years, Immunome's EPS (Basic) ranged from a high of -$0.35 in Q1 2023 and a low of -$4.22 during Q4 2023.
  • Over the past 3 years, Immunome's median EPS (Basic) value was -$0.60 (recorded in 2024), while the average stood at -$1.11.
  • Its EPS (Basic) has fluctuated over the past 5 years, first plummeted by 617.14% in 2024, then surged by 79.28% in 2025.
  • Immunome's EPS (Basic) (Quarterly) stood at -$4.22 in 2023, then soared by 69.67% to -$1.28 in 2024, then rose by 16.67% to -$0.65 in 2025.
  • Its last three reported values are -$0.65 in Q3 2025, -$0.50 for Q2 2025, and -$0.52 during Q1 2025.